WA
AGIO icon

Winfield Associates’s Agios Pharmaceuticals AGIO Stock Holding History

Winfield Associates’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10
Closed – – 690
2016
Q2 		$0 Hold
10
– – ﹤0.01% 701
2016
Q1 		$0 Buy
+10
New +$428 ﹤0.01% 685

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Winfield Associates's AGIO Position: Q3 2016 in Review

Winfield Associates sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 10 shares.

Winfield Associates first reported a position in AGIO in Q1 2016 and held it in 2 quarters. The position peaked at $0 in Q2 2016. 163 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • Winfield Associates reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Winfield Associates sold 10 Agios Pharmaceuticals shares in Q3 2016.
  • Winfield Associates first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Winfield Associates's Agios Pharmaceuticals position peaked at $0 in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on Winfield Associates's 13F filing for Q3 2016, filed 31 Oct 2016.